Form 8-K - Current report:
SEC Accession No. 0001564590-20-046215
Filing Date
2020-10-09
Accepted
2020-10-09 17:00:32
Documents
15
Period of Report
2020-10-07
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K arwr-8k_20201007.htm   iXBRL 8-K 40454
2 EX-99.1 arwr-ex991_34.htm EX-99.1 53159
3 GRAPHIC gn1ra4fhlkjg000002.jpg GRAPHIC 53604
4 GRAPHIC gn1ra4fhlkjg000001.jpg GRAPHIC 33580
  Complete submission text file 0001564590-20-046215.txt   355619

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA arwr-20201007.xsd EX-101.SCH 5812
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE arwr-20201007_lab.xml EX-101.LAB 19478
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE arwr-20201007_pre.xml EX-101.PRE 11657
8 EXTRACTED XBRL INSTANCE DOCUMENT arwr-8k_20201007_htm.xml XML 3565
Mailing Address 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105
Business Address 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105 626-696-4702
ARROWHEAD PHARMACEUTICALS, INC. (Filer) CIK: 0000879407 (see all company filings)

EIN.: 460408024 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-38042 | Film No.: 201233800
SIC: 2834 Pharmaceutical Preparations